ECSP15007420A - Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno - Google Patents
Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógenoInfo
- Publication number
- ECSP15007420A ECSP15007420A ECIEPI20157420A ECPI201507420A ECSP15007420A EC SP15007420 A ECSP15007420 A EC SP15007420A EC IEPI20157420 A ECIEPI20157420 A EC IEPI20157420A EC PI201507420 A ECPI201507420 A EC PI201507420A EC SP15007420 A ECSP15007420 A EC SP15007420A
- Authority
- EC
- Ecuador
- Prior art keywords
- androgen receptor
- methods
- modified
- present
- compositions
- Prior art date
Links
- 102000001307 androgen receptors Human genes 0.000 title abstract 8
- 108010080146 androgen receptors Proteins 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000000849 selective androgen receptor modulator Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
Abstract
En la presente descripción se describen polipéptidos del receptor de andrógeno modificado que son resistentes a la inhibición por un inhibidor del receptor de andrógeno. En la presente invención se describen composiciones, combinaciones y estuches que contienen los polipéptidos del receptor de andrógeno modificados y métodos de uso de los polipéptidos del receptor de andrógeno modificados. En la presente invención se describen, además, métodos de uso de los polipéptidos del receptor de andrógeno modificados como agentes de análisis para la identificación y el diseño de moduladores del receptor de andrógeno de tercera generación. En la presente invención se describen, además, moduladores del receptor de andrógeno de tercera generación que inhiben la actividad de los polipéptidos del receptor de andrógeno modificados. Se describen, además, composiciones farmacéuticas y medicamentos que incluyen los compuestos que se describen en la presente invención, así como también métodos de uso de tales moduladores del receptor de andrógeno, solos y en combinación con otros compuestos, para el tratamiento de enfermedades o condiciones, lo que incluye a los cánceres, tales como los cánceres de próstata resistentes a la castración, que son mediados o dependientes de los receptores de andrógeno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261676842P | 2012-07-27 | 2012-07-27 | |
US201361783763P | 2013-03-14 | 2013-03-14 | |
US201361829123P | 2013-05-30 | 2013-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP15007420A true ECSP15007420A (es) | 2016-01-29 |
Family
ID=48948536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI20157420A ECSP15007420A (es) | 2012-07-27 | 2015-02-27 | Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno |
Country Status (34)
Country | Link |
---|---|
US (2) | US9617602B2 (es) |
EP (2) | EP3653733A1 (es) |
JP (3) | JP6297556B2 (es) |
KR (2) | KR102210183B1 (es) |
CN (3) | CN104685072A (es) |
AU (3) | AU2013295543B2 (es) |
BR (2) | BR112015001801A2 (es) |
CA (1) | CA2879926A1 (es) |
CL (1) | CL2015000194A1 (es) |
CO (1) | CO7280477A2 (es) |
CR (1) | CR20150022A (es) |
CY (1) | CY1122651T1 (es) |
DK (1) | DK2877599T3 (es) |
EA (2) | EA029563B1 (es) |
EC (1) | ECSP15007420A (es) |
ES (1) | ES2764381T3 (es) |
GT (1) | GT201500019A (es) |
HK (1) | HK1211060A1 (es) |
HR (1) | HRP20192342T1 (es) |
HU (1) | HUE047781T2 (es) |
IL (2) | IL236844B (es) |
LT (1) | LT2877599T (es) |
MX (2) | MX370507B (es) |
NI (1) | NI201500004A (es) |
NZ (4) | NZ744288A (es) |
PE (3) | PE20190845A1 (es) |
PH (2) | PH12015500175A1 (es) |
PL (1) | PL2877599T3 (es) |
PT (1) | PT2877599T (es) |
RS (1) | RS59812B1 (es) |
SG (2) | SG11201500184TA (es) |
SI (1) | SI2877599T1 (es) |
UA (1) | UA118178C2 (es) |
WO (1) | WO2014018926A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2721506C (en) | 2008-04-16 | 2019-09-17 | Jun Luo | Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants |
AU2012353660A1 (en) | 2011-12-16 | 2014-06-12 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
EP2839028B1 (en) | 2012-04-20 | 2016-12-28 | Cepheid | Methods of detecting bladder cancer |
EP2912194B1 (en) * | 2012-10-26 | 2019-05-08 | Memorial Sloan-Kettering Cancer Center | Androgen receptor variants and methods for making and using |
ES2798899T3 (es) * | 2013-02-25 | 2020-12-14 | Novartis Ag | Mutación novedosa del receptor de andrógenos |
ES2715874T3 (es) | 2013-03-06 | 2019-06-06 | Cepheid | Métodos de detección del cáncer de la vejiga |
EP4066841A1 (en) | 2013-03-14 | 2022-10-05 | University of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
SG11201600525XA (en) | 2013-08-12 | 2016-02-26 | Tokai Pharmaceuticals Inc | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
KR20200015830A (ko) * | 2014-02-05 | 2020-02-12 | 레크 파마슈티칼스 디.디. | 안드로겐 수용체 길항제의 고체 제약 조성물 |
US10774387B2 (en) | 2014-05-19 | 2020-09-15 | The Johns Hopkins University | Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer |
WO2016033114A1 (en) * | 2014-08-25 | 2016-03-03 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
US11369319B2 (en) | 2016-03-29 | 2022-06-28 | Roche Diabetes Care, Inc. | Method of operating a receiver for receiving analyte data, receiver and computer program product |
US11702702B2 (en) * | 2016-04-15 | 2023-07-18 | Predicine, Inc. | Systems and methods for detecting genetic alterations |
CN106405085B (zh) * | 2016-08-31 | 2018-03-27 | 天津市泌尿外科研究所 | 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法 |
CN106290919B (zh) * | 2016-08-31 | 2018-03-27 | 天津市泌尿外科研究所 | 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法 |
CN106198985B (zh) * | 2016-08-31 | 2018-03-27 | 天津市泌尿外科研究所 | 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法 |
CN106526185B (zh) * | 2016-10-28 | 2018-03-30 | 拜尔康(天津)医药科技有限公司 | 用于检测去势抵抗性前列腺癌的elisa试剂盒及检测方法 |
ES2884064T3 (es) * | 2016-12-16 | 2021-12-10 | Kangpu Biopharmaceuticals Ltd | Composición combinada que comprende un compuesto benzoheterocíclico y un modulador de la vía de los receptores androgénicos y usos de la misma |
SG11202003122XA (en) * | 2017-10-19 | 2020-05-28 | Univ Yale | Inhibition of androgen receptor by extracts of medicinal herbs and compositions thereof |
CN108018342A (zh) * | 2017-12-04 | 2018-05-11 | 合肥艾迪康临床检验所有限公司 | 检测ar基因突变的引物和方法 |
JP6993683B2 (ja) | 2017-12-15 | 2022-01-13 | 東都興業株式会社 | ビニールハウスにおけるシート押え紐の止め具 |
CN109115742A (zh) * | 2018-09-05 | 2019-01-01 | 中国农业科学院农业质量标准与检测技术研究所 | 一种抗雄激素效应的检测方法 |
CN109321569B (zh) * | 2018-10-29 | 2022-04-12 | 迈杰转化医学研究(苏州)有限公司 | 一种引物探针组合物及其应用 |
KR102473989B1 (ko) | 2018-11-28 | 2022-12-07 | (주)바이오니아 | 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물 |
JP2022549222A (ja) * | 2019-09-23 | 2022-11-24 | アキュター バイオテクノロジー インコーポレイテッド | アンドロゲン受容体分解活性を有する新規尿素およびその使用 |
GB201914296D0 (en) * | 2019-10-03 | 2019-11-20 | Univ Oxford Innovation Ltd | Treatment |
WO2021110731A1 (en) * | 2019-12-03 | 2021-06-10 | Bayer Aktiengesellschaft | Method for determining the response of prostate cancer patients to treatment with androgen receptor antagonists based on gene expression changes or super-enhancer protein-binding profiles |
CN113533730B (zh) * | 2021-07-23 | 2022-09-06 | 南方医科大学深圳医院 | 一种血浆外泌体标志物组合及其应用 |
WO2024001989A1 (en) * | 2022-06-27 | 2024-01-04 | Etern Biopharma (Shanghai) Co., Ltd. | Compositions and methods for modulating molecules |
CN117860773B (zh) * | 2023-11-28 | 2024-07-16 | 四川大学华西医院 | 促进ar基因甲基化的药物及其在预防或治疗雄性激素脱发中的用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
AU690131B2 (en) | 1993-07-26 | 1998-04-23 | Variagenics, Inc. | Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
US6200754B1 (en) | 1998-03-19 | 2001-03-13 | Variagenics, Inc. | Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes |
GB0005689D0 (en) * | 2000-03-09 | 2000-05-03 | Schering Ag | Crystal |
US6960474B2 (en) * | 2000-06-28 | 2005-11-01 | Bristol-Myers Squibb Company | Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator |
NZ550102A (en) * | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
MX2010005703A (es) * | 2007-11-26 | 2010-06-11 | Enzon Pharmaceuticals Inc | Antagonistas de acido nucleico entrelazado que eligen como objetivo al receptor de androgeno. |
EP2065474A1 (en) * | 2007-11-28 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | A method to assess prognosis and to predict therapeutic response to endocrine treatment |
US8133724B2 (en) * | 2008-09-17 | 2012-03-13 | University Of Maryland, Baltimore | Human androgen receptor alternative splice variants as biomarkers and therapeutic targets |
JP5631382B2 (ja) * | 2009-04-03 | 2014-11-26 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 複合材料の製造方法 |
GEP20146138B (en) * | 2009-10-23 | 2014-08-11 | Panacela Labs Inc | Method for treating androgen receptor positive cancers |
-
2013
- 2013-07-26 EA EA201590290A patent/EA029563B1/ru unknown
- 2013-07-26 JP JP2015524483A patent/JP6297556B2/ja not_active Expired - Fee Related
- 2013-07-26 KR KR1020157004875A patent/KR102210183B1/ko active IP Right Grant
- 2013-07-26 NZ NZ744288A patent/NZ744288A/en not_active IP Right Cessation
- 2013-07-26 US US14/417,515 patent/US9617602B2/en active Active
- 2013-07-26 NZ NZ740700A patent/NZ740700A/en not_active IP Right Cessation
- 2013-07-26 PT PT137459731T patent/PT2877599T/pt unknown
- 2013-07-26 BR BR112015001801A patent/BR112015001801A2/pt not_active IP Right Cessation
- 2013-07-26 CN CN201380050780.4A patent/CN104685072A/zh active Pending
- 2013-07-26 RS RS20191677A patent/RS59812B1/sr unknown
- 2013-07-26 LT LTEP13745973.1T patent/LT2877599T/lt unknown
- 2013-07-26 EA EA201792520A patent/EA035535B1/ru unknown
- 2013-07-26 UA UAA201501717A patent/UA118178C2/uk unknown
- 2013-07-26 WO PCT/US2013/052395 patent/WO2014018926A1/en active Application Filing
- 2013-07-26 AU AU2013295543A patent/AU2013295543B2/en not_active Ceased
- 2013-07-26 NZ NZ742581A patent/NZ742581A/en not_active IP Right Cessation
- 2013-07-26 EP EP19204705.8A patent/EP3653733A1/en not_active Withdrawn
- 2013-07-26 CN CN201911199159.XA patent/CN110845626A/zh active Pending
- 2013-07-26 PE PE2019001034A patent/PE20190845A1/es unknown
- 2013-07-26 CA CA2879926A patent/CA2879926A1/en not_active Abandoned
- 2013-07-26 MX MX2015001209A patent/MX370507B/es active IP Right Grant
- 2013-07-26 NZ NZ704487A patent/NZ704487A/en not_active IP Right Cessation
- 2013-07-26 BR BR122017017921A patent/BR122017017921A2/pt not_active Application Discontinuation
- 2013-07-26 HU HUE13745973A patent/HUE047781T2/hu unknown
- 2013-07-26 PL PL13745973T patent/PL2877599T3/pl unknown
- 2013-07-26 KR KR1020217002584A patent/KR20210012064A/ko not_active Application Discontinuation
- 2013-07-26 DK DK13745973.1T patent/DK2877599T3/da active
- 2013-07-26 CN CN201711405848.2A patent/CN108048567A/zh active Pending
- 2013-07-26 PE PE2019000439A patent/PE20190574A1/es unknown
- 2013-07-26 ES ES13745973T patent/ES2764381T3/es active Active
- 2013-07-26 SG SG11201500184TA patent/SG11201500184TA/en unknown
- 2013-07-26 SI SI201331612T patent/SI2877599T1/sl unknown
- 2013-07-26 EP EP13745973.1A patent/EP2877599B1/en active Active
- 2013-07-26 SG SG10201703254VA patent/SG10201703254VA/en unknown
- 2013-07-26 PE PE2015000095A patent/PE20150644A1/es active IP Right Grant
-
2015
- 2015-01-21 CR CR20150022A patent/CR20150022A/es unknown
- 2015-01-22 IL IL236844A patent/IL236844B/en active IP Right Grant
- 2015-01-26 NI NI201500004A patent/NI201500004A/es unknown
- 2015-01-26 CL CL2015000194A patent/CL2015000194A1/es unknown
- 2015-01-26 MX MX2019015148A patent/MX2019015148A/es unknown
- 2015-01-27 PH PH12015500175A patent/PH12015500175A1/en unknown
- 2015-01-28 GT GT201500019A patent/GT201500019A/es unknown
- 2015-02-04 CO CO15022272A patent/CO7280477A2/es unknown
- 2015-02-27 EC ECIEPI20157420A patent/ECSP15007420A/es unknown
- 2015-12-02 HK HK15111856.3A patent/HK1211060A1/xx unknown
-
2017
- 2017-03-01 US US15/446,341 patent/US20170196840A1/en not_active Abandoned
- 2017-05-19 AU AU2017203385A patent/AU2017203385B2/en not_active Ceased
-
2018
- 2018-02-21 JP JP2018028558A patent/JP6592545B2/ja not_active Expired - Fee Related
- 2018-11-26 PH PH12018502500A patent/PH12018502500A1/en unknown
-
2019
- 2019-03-13 AU AU2019201726A patent/AU2019201726B2/en not_active Expired - Fee Related
- 2019-03-25 IL IL265610A patent/IL265610B/en active IP Right Grant
- 2019-09-20 JP JP2019171022A patent/JP2020072655A/ja not_active Ceased
- 2019-12-30 HR HRP20192342TT patent/HRP20192342T1/hr unknown
-
2020
- 2020-01-14 CY CY20201100029T patent/CY1122651T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP15007420A (es) | Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno | |
CL2015001508A1 (es) | Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros. | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
BR112014014124A2 (pt) | Moduladores do receptor de estrogênio fluorados e usos dos mesmos | |
CO6680708A2 (es) | Compuesto modulares de estrógenos y composiciones que comprenden los mismos | |
NI201500093A (es) | Modulador del receptor de andrógenos y usos de este | |
GT201300122A (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
UY32327A (es) | Antagonistas de receptores de ácido lisofosfatídico | |
EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
DOP2014000114A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
CL2019001091A1 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas. | |
UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
GT201600255A (es) | Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativas | |
EA202090782A1 (ru) | Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор | |
CU20140058A7 (es) | Nuevos 2h-indizoles como antagonistas del receptor ep-2 | |
UY32679A (es) | Antagonistas policíclicos de receptores de ácido lisofosfatidico |